BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Garg AD, Vara Perez M, Schaaf M, Agostinis P, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Dendritic cell-based anticancer immunotherapy. Oncoimmunology 2017;6:e1328341. [PMID: 28811970 DOI: 10.1080/2162402X.2017.1328341] [Cited by in Crossref: 50] [Cited by in F6Publishing: 45] [Article Influence: 10.0] [Reference Citation Analysis]
Number Citing Articles
1 Versteven M, Van den Bergh JMJ, Marcq E, Smits ELJ, Van Tendeloo VFI, Hobo W, Lion E. Dendritic Cells and Programmed Death-1 Blockade: A Joint Venture to Combat Cancer. Front Immunol 2018;9:394. [PMID: 29599770 DOI: 10.3389/fimmu.2018.00394] [Cited by in Crossref: 53] [Cited by in F6Publishing: 52] [Article Influence: 13.3] [Reference Citation Analysis]
2 Morisaki T, Morisaki T, Kubo M, Morisaki S, Nakamura Y, Onishi H. Lymph Nodes as Anti-Tumor Immunotherapeutic Tools: Intranodal-Tumor-Specific Antigen-Pulsed Dendritic Cell Vaccine Immunotherapy. Cancers 2022;14:2438. [DOI: 10.3390/cancers14102438] [Reference Citation Analysis]
3 Wang Z, Wang Z, Li B, Wang S, Chen T, Ye Z. Innate Immune Cells: A Potential and Promising Cell Population for Treating Osteosarcoma. Front Immunol 2019;10:1114. [PMID: 31156651 DOI: 10.3389/fimmu.2019.01114] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 6.7] [Reference Citation Analysis]
4 Grees M, Sharbi-Yunger A, Evangelou C, Baumann D, Cafri G, Tzehoval E, Eichmüller SB, Offringa R, Utikal J, Eisenbach L, Umansky V. Optimized dendritic cell vaccination induces potent CD8 T cell responses and anti-tumor effects in transgenic mouse melanoma models. Oncoimmunology 2018;7:e1445457. [PMID: 29900058 DOI: 10.1080/2162402X.2018.1445457] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
5 Garg AD, More S, Rufo N, Mece O, Sassano ML, Agostinis P, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics. Oncoimmunology 2017;6:e1386829. [PMID: 29209573 DOI: 10.1080/2162402X.2017.1386829] [Cited by in Crossref: 124] [Cited by in F6Publishing: 77] [Article Influence: 24.8] [Reference Citation Analysis]
6 Chanier T, Chames P. Nanobody Engineering: Toward Next Generation Immunotherapies and Immunoimaging of Cancer. Antibodies (Basel) 2019;8:E13. [PMID: 31544819 DOI: 10.3390/antib8010013] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 14.0] [Reference Citation Analysis]
7 Mashima H, Zhang R, Kobayashi T, Hagiya Y, Tsukamoto H, Liu T, Iwama T, Yamamoto M, Lin C, Nakatsuka R, Mishima Y, Watanabe N, Yamada T, Senju S, Kaneko S, Idiris A, Nakatsura T, Ohdan H, Uemura Y. Generation of GM-CSF-producing antigen-presenting cells that induce a cytotoxic T cell-mediated antitumor response. Oncoimmunology 2020;9:1814620. [PMID: 33457097 DOI: 10.1080/2162402X.2020.1814620] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Sprooten J, Ceusters J, Coosemans A, Agostinis P, De Vleeschouwer S, Zitvogel L, Kroemer G, Galluzzi L, Garg AD. Trial watch: dendritic cell vaccination for cancer immunotherapy. Oncoimmunology 2019;8:e1638212. [PMID: 31646087 DOI: 10.1080/2162402X.2019.1638212] [Cited by in Crossref: 51] [Cited by in F6Publishing: 35] [Article Influence: 17.0] [Reference Citation Analysis]
9 Bernal-Estévez DA, Ortíz Barbosa MA, Ortíz-Montero P, Cifuentes C, Sánchez R, Parra-López CA. Autologous Dendritic Cells in Combination With Chemotherapy Restore Responsiveness of T Cells in Breast Cancer Patients: A Single-Arm Phase I/II Trial. Front Immunol 2021;12:669965. [PMID: 34489928 DOI: 10.3389/fimmu.2021.669965] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Cho KM, Kim MS, Jung HJ, Choi EJ, Kim TS. Mst1-Deficiency Induces Hyperactivation of Monocyte-Derived Dendritic Cells via Akt1/c-myc Pathway. Front Immunol 2019;10:2142. [PMID: 31572367 DOI: 10.3389/fimmu.2019.02142] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
11 Raaijmakers TK, Ansems M. Microenvironmental derived factors modulating dendritic cell function and vaccine efficacy: the effect of prostanoid receptor and nuclear receptor ligands. Cancer Immunol Immunother 2018;67:1789-96. [PMID: 29998375 DOI: 10.1007/s00262-018-2205-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
12 Fucikova J, Palova-Jelinkova L, Bartunkova J, Spisek R. Induction of Tolerance and Immunity by Dendritic Cells: Mechanisms and Clinical Applications. Front Immunol 2019;10:2393. [PMID: 31736936 DOI: 10.3389/fimmu.2019.02393] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 11.3] [Reference Citation Analysis]
13 Castiello L, Aricò E, D'Agostino G, Santodonato L, Belardelli F. In situ Vaccination by Direct Dendritic Cell Inoculation: The Coming of Age of an Old Idea? Front Immunol 2019;10:2303. [PMID: 31611878 DOI: 10.3389/fimmu.2019.02303] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
14 Lamberti MJ, Nigro A, Mentucci FM, Rumie Vittar NB, Casolaro V, Dal Col J. Dendritic Cells and Immunogenic Cancer Cell Death: A Combination for Improving Antitumor Immunity. Pharmaceutics 2020;12:E256. [PMID: 32178288 DOI: 10.3390/pharmaceutics12030256] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
15 Hargadon KM. Strategies to Improve the Efficacy of Dendritic Cell-Based Immunotherapy for Melanoma. Front Immunol 2017;8:1594. [PMID: 29209327 DOI: 10.3389/fimmu.2017.01594] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 5.2] [Reference Citation Analysis]
16 Smith M, García-Martínez E, Pitter MR, Fucikova J, Spisek R, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Toll-like receptor agonists in cancer immunotherapy. Oncoimmunology 2018;7:e1526250. [PMID: 30524908 DOI: 10.1080/2162402X.2018.1526250] [Cited by in Crossref: 90] [Cited by in F6Publishing: 44] [Article Influence: 22.5] [Reference Citation Analysis]
17 Lisini D, Lettieri S, Nava S, Accordino G, Frigerio S, Bortolotto C, Lancia A, Filippi AR, Agustoni F, Pandolfi L, Piloni D, Comoli P, Corsico AG, Stella GM. Local Therapies and Modulation of Tumor Surrounding Stroma in Malignant Pleural Mesothelioma: A Translational Approach. Int J Mol Sci 2021;22:9014. [PMID: 34445720 DOI: 10.3390/ijms22169014] [Reference Citation Analysis]
18 van Dinther D, Lopez Venegas M, Veninga H, Olesek K, Hoogterp L, Revet M, Ambrosini M, Kalay H, Stöckl J, van Kooyk Y, den Haan JMM. Activation of CD8⁺ T Cell Responses after Melanoma Antigen Targeting to CD169⁺ Antigen Presenting Cells in Mice and Humans. Cancers (Basel) 2019;11:E183. [PMID: 30764534 DOI: 10.3390/cancers11020183] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
19 Collignon A, Silvy F, Robert S, Trad M, Germain S, Nigri J, André F, Rigot V, Tomasini R, Bonnotte B, Lombardo D, Mas E, Beraud E. Dendritic cell-based vaccination: powerful resources of immature dendritic cells against pancreatic adenocarcinoma. Oncoimmunology 2018;7:e1504727. [PMID: 30524902 DOI: 10.1080/2162402X.2018.1504727] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
20 Gou S, Wang S, Liu W, Chen G, Zhang D, Du J, Yan Z, Wang H, Zhai W, Sui X, Wu Y, Qi Y, Gao Y. Adjuvant-free peptide vaccine targeting Clec9a on dendritic cells can induce robust antitumor immune response through Syk/IL-21 axis. Theranostics 2021;11:7308-21. [PMID: 34158852 DOI: 10.7150/thno.56406] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Baldin AV, Savvateeva LV, Bazhin AV, Zamyatnin AA Jr. Dendritic Cells in Anticancer Vaccination: Rationale for Ex Vivo Loading or In Vivo Targeting. Cancers (Basel) 2020;12:E590. [PMID: 32150821 DOI: 10.3390/cancers12030590] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]
22 Est-witte SE, Livingston NK, Omotoso MO, Green JJ, Schneck JP. Nanoparticles for generating antigen-specific T cells for immunotherapy. Seminars in Immunology 2021. [DOI: 10.1016/j.smim.2021.101541] [Reference Citation Analysis]
23 Liu PH, Sidi S. Targeting the Innate Immune Kinase IRAK1 in Radioresistant Cancer: Double-Edged Sword or One-Two Punch? Front Oncol 2019;9:1174. [PMID: 31799178 DOI: 10.3389/fonc.2019.01174] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
24 Nijen Twilhaar MK, Czentner L, Grabowska J, Affandi AJ, Lau CYJ, Olesek K, Kalay H, van Nostrum CF, van Kooyk Y, Storm G, Haan JMMD. Optimization of Liposomes for Antigen Targeting to Splenic CD169+ Macrophages. Pharmaceutics 2020;12:E1138. [PMID: 33255564 DOI: 10.3390/pharmaceutics12121138] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
25 Humeau J, Le Naour J, Galluzzi L, Kroemer G, Pol JG. Trial watch: intratumoral immunotherapy. Oncoimmunology 2021;10:1984677. [PMID: 34676147 DOI: 10.1080/2162402X.2021.1984677] [Reference Citation Analysis]
26 Azeem W, Bakke RM, Gabriel B, Appel S, Øyan AM, Kalland KH. Evaluation of β-Catenin Inhibition of Axitinib and Nitazoxanide in Human Monocyte-Derived Dendritic Cells. Biomedicines 2021;9:949. [PMID: 34440153 DOI: 10.3390/biomedicines9080949] [Reference Citation Analysis]
27 Chrisikos TT, Zhou Y, Slone N, Babcock R, Watowich SS, Li HS. Molecular regulation of dendritic cell development and function in homeostasis, inflammation, and cancer. Mol Immunol 2019;110:24-39. [PMID: 29549977 DOI: 10.1016/j.molimm.2018.01.014] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 4.5] [Reference Citation Analysis]
28 Gessani S, Belardelli F. Immune Dysfunctions and Immunotherapy in Colorectal Cancer: The Role of Dendritic Cells. Cancers (Basel) 2019;11:E1491. [PMID: 31623355 DOI: 10.3390/cancers11101491] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
29 Wang B, Guo H, Xu H, Chen Y, Zhao G, Yu H. The Role of Graphene Oxide Nanocarriers in Treating Gliomas. Front Oncol 2022;12:736177. [DOI: 10.3389/fonc.2022.736177] [Reference Citation Analysis]
30 Li S, Wu J, Zhu S, Liu YJ, Chen J. Disease-Associated Plasmacytoid Dendritic Cells. Front Immunol 2017;8:1268. [PMID: 29085361 DOI: 10.3389/fimmu.2017.01268] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 5.8] [Reference Citation Analysis]
31 Hanada S, Tsuruta T, Haraguchi K, Okamoto M, Sugiyama H, Koido S. Long-term survival of pancreatic cancer patients treated with multimodal therapy combined with WT1-targeted dendritic cell vaccines. Hum Vaccin Immunother 2019;15:397-406. [PMID: 30230959 DOI: 10.1080/21645515.2018.1524238] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
32 Eagles ME, Nassiri F, Badhiwala JH, Suppiah S, Almenawer SA, Zadeh G, Aldape KD. Dendritic cell vaccines for high-grade gliomas. Ther Clin Risk Manag 2018;14:1299-313. [PMID: 30100728 DOI: 10.2147/TCRM.S135865] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 4.5] [Reference Citation Analysis]
33 Bhargava A, Srivastava RK, Mishra DK, Tiwari RR, Sharma RS, Mishra PK. Dendritic cell engineering for selective targeting of female reproductive tract cancers. Indian J Med Res 2018;148:S50-63. [PMID: 30964081 DOI: 10.4103/ijmr.IJMR_224_18] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
34 García-Martínez E, Smith M, Buqué A, Aranda F, de la Peña FA, Ivars A, Cánovas MS, Conesa MAV, Fucikova J, Spisek R, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy. Oncoimmunology 2018;7:e1433982. [PMID: 29872569 DOI: 10.1080/2162402X.2018.1433982] [Cited by in Crossref: 25] [Cited by in F6Publishing: 9] [Article Influence: 6.3] [Reference Citation Analysis]
35 Mookerjee A, Graciotti M, Kandalaft LE, Kandalaft L. A cancer vaccine with dendritic cells differentiated with GM-CSF and IFNα and pulsed with a squaric acid treated cell lysate improves T cell priming and tumor growth control in a mouse model. Bioimpacts 2018;8:211-21. [PMID: 30211081 DOI: 10.15171/bi.2018.24] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
36 Cosentino G, Plantamura I, Tagliabue E, Iorio MV, Cataldo A. Breast Cancer Drug Resistance: Overcoming the Challenge by Capitalizing on MicroRNA and Tumor Microenvironment Interplay. Cancers (Basel) 2021;13:3691. [PMID: 34359591 DOI: 10.3390/cancers13153691] [Reference Citation Analysis]
37 Jiang E, Yan T, Xu Z, Shang Z. Tumor Microenvironment and Cell Fusion. Biomed Res Int 2019;2019:5013592. [PMID: 31380426 DOI: 10.1155/2019/5013592] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
38 Lamberti MJ, Mentucci FM, Roselli E, Araya P, Rivarola VA, Rumie Vittar NB, Maccioni M. Photodynamic Modulation of Type 1 Interferon Pathway on Melanoma Cells Promotes Dendritic Cell Activation. Front Immunol. 2019;10:2614. [PMID: 31781113 DOI: 10.3389/fimmu.2019.02614] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
39 Mookerjee A, Graciotti M, Kandalaft LE. IL-15 and a Two-Step Maturation Process Improve Bone Marrow-Derived Dendritic Cell Cancer Vaccine. Cancers (Basel) 2019;11:E40. [PMID: 30621204 DOI: 10.3390/cancers11010040] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
40 Lecocq Q, De Vlaeminck Y, Hanssens H, D'Huyvetter M, Raes G, Goyvaerts C, Keyaerts M, Devoogdt N, Breckpot K. Theranostics in immuno-oncology using nanobody derivatives. Theranostics 2019;9:7772-91. [PMID: 31695800 DOI: 10.7150/thno.34941] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 13.7] [Reference Citation Analysis]
41 Cornel AM, van Til NP, Boelens JJ, Nierkens S. Strategies to Genetically Modulate Dendritic Cells to Potentiate Anti-Tumor Responses in Hematologic Malignancies. Front Immunol 2018;9:982. [PMID: 29867960 DOI: 10.3389/fimmu.2018.00982] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
42 Tel-Karthaus N, Kers-Rebel ED, Looman MW, Ichinose H, de Vries CJ, Ansems M. Nuclear Receptor Nur77 Deficiency Alters Dendritic Cell Function. Front Immunol 2018;9:1797. [PMID: 30123220 DOI: 10.3389/fimmu.2018.01797] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
43 Zhang L, Du J, Song Q, Zhang C, Wu X, Rughetti A. A Novel In Situ Dendritic Cell Vaccine Triggered by Rose Bengal Enhances Adaptive Antitumour Immunity. Journal of Immunology Research 2022;2022:1-17. [DOI: 10.1155/2022/1178874] [Reference Citation Analysis]
44 Clappaert EJ, Murgaski A, Van Damme H, Kiss M, Laoui D. Diamonds in the Rough: Harnessing Tumor-Associated Myeloid Cells for Cancer Therapy. Front Immunol 2018;9:2250. [PMID: 30349530 DOI: 10.3389/fimmu.2018.02250] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
45 Pallerla S, Abdul AURM, Comeau J, Jois S. Cancer Vaccines, Treatment of the Future: With Emphasis on HER2-Positive Breast Cancer. Int J Mol Sci 2021;22:E779. [PMID: 33466691 DOI: 10.3390/ijms22020779] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
46 Zheng H, Liu L, Zhang H, Kan F, Wang S, Li Y, Tian H, Meng S. Dendritic cells pulsed with placental gp96 promote tumor-reactive immune responses. PLoS One 2019;14:e0211490. [PMID: 30703157 DOI: 10.1371/journal.pone.0211490] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
47 Saxena M, Balan S, Roudko V, Bhardwaj N. Towards superior dendritic-cell vaccines for cancer therapy. Nat Biomed Eng 2018;2:341-6. [PMID: 30116654 DOI: 10.1038/s41551-018-0250-x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 10.8] [Reference Citation Analysis]
48 Mastelic-Gavillet B, Balint K, Boudousquie C, Gannon PO, Kandalaft LE. Personalized Dendritic Cell Vaccines-Recent Breakthroughs and Encouraging Clinical Results. Front Immunol 2019;10:766. [PMID: 31031762 DOI: 10.3389/fimmu.2019.00766] [Cited by in Crossref: 55] [Cited by in F6Publishing: 51] [Article Influence: 18.3] [Reference Citation Analysis]
49 Mensali N, Grenov A, Pati NB, Dillard P, Myhre MR, Gaudernack G, Kvalheim G, Inderberg EM, Bakke O, Wälchli S. Antigen-delivery through invariant chain (CD74) boosts CD8 and CD4 T cell immunity. Oncoimmunology 2019;8:1558663. [PMID: 30723591 DOI: 10.1080/2162402X.2018.1558663] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]